Gajewski James
Hebei Yanda Lu Daopei Hospital (consultant), China.
Blood Cell Ther. 2020 May 25;3(3):37-43. doi: 10.31547/bct-2019-016. eCollection 2020 Aug 25.
Hematopoietic cellular transplantation (HCT) has impacted medicine beyond simply treating certain diseases. Allogeneic HCT was the first documented successful immunological cellular therapy. Its usage continues to increase. The immunological disparity between donor and recipient has been associated with better antitumor efficacy as well as immunological toxicities. Through active clinical trials and research, considerable improvements in HCT therapy have been made over the past 50 years. The HCT international outcomes registry has considerably contributed to these improvements by identifying factors that could never be studied by a single center. With the use of unrelated donors, international collaboration increased as donor cell access through registries was not inhibited by international boundaries. HCT as a field pioneered the development of organizations for self-regulation that were assessing the entire program as an integrated whole rather than simply assessing facilities and providers separately.
造血细胞移植（HCT）对医学的影响已不仅仅局限于治疗某些特定疾病。同种异体造血细胞移植是首个有记录的成功免疫细胞疗法，其应用持续增加。供体与受体之间的免疫差异与更好的抗肿瘤疗效以及免疫毒性相关。通过积极的临床试验和研究，在过去50年里造血细胞移植疗法取得了显著进展。造血细胞移植国际成果登记处通过识别单个中心无法研究的因素，为这些进展做出了重大贡献。随着无关供体的使用，国际合作增加，因为通过登记处获取供体细胞不受国界限制。造血细胞移植领域率先发展了自我监管组织，这些组织将整个项目作为一个整体进行评估，而不是简单地分别评估设施和供应商。
